Medexus Pharmaceuticals (OTCMKTS:MEDXF) Stock Price Down 3% – Should You Sell?

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF)’s share price dropped 3% during mid-day trading on Tuesday . The company traded as low as $1.87 and last traded at $1.87. Approximately 335 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 28,374 shares. The stock had previously closed at $1.93.

Wall Street Analyst Weigh In

Separately, Raymond James restated a “strong-buy” rating on shares of Medexus Pharmaceuticals in a report on Monday, February 3rd.

Medexus Pharmaceuticals Price Performance

The business’s fifty day moving average is $1.81 and its 200-day moving average is $2.04.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.